Isatuximab, lenalidomide, bortezomib and dexamethasone as induction therapy show...
Dr Elias Mai - University Hospital Heidelberg, Heidelberg, Germany
Isatuximab, lenalidomide, bortezomib and dexamethasone as induction therapy show a superior MRD negativity rate for newly diagnosed MM patients ( Dr Elias Mai - University Hospital Heidelberg, Heidelberg, Germany )
13 Jun 2022
Spotlight on global cancer control at ASCO 2022
Prof Eduardo Cazap - Editor-in-Chief, ecancer and SLACOM
Spotlight on global cancer control at ASCO 2022 ( Prof Eduardo Cazap - Editor-in-Chief, ecancer and SLACOM )
10 Jun 2022
UICC announces global coalition to increase access to essential cancer medicines...
Dr Cary Adams - Chief Executive Officer, Union for International Cancer Control
UICC announces global coalition to increase access to essential cancer medicines in low and lower middle-income countries ( Dr Cary Adams - Chief Executive Officer, Union for International Cancer Control )
9 Jun 2022
Momelotinib superior to danazol in symptomatic and anaemic myelofibrosis patient...
Dr Ruben A. Mesa - UT Health San Antonio MD Anderson Cancer Center, San Antonio,...
Momelotinib superior to danazol in symptomatic and anaemic myelofibrosis patients previously treated with a JAK inhibitor ( Dr Ruben A. Mesa - UT Health San Antonio MD Anderson Cancer Center, San Antonio, USA )
7 Jun 2022
OncoAlert and ecancer weekly round up for October 11th - October 16, 2021
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
OncoAlert and ecancer weekly round up for October 11th - October 16, 2021 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )
18 Oct 2021
Iberdomide in combination with dexamethasone and daratumumab, bortezomib, or car...
Prof Sagar Lonial - Winship Cancer Institute of Emory University, Atlanta, USA
Iberdomide in combination with dexamethasone and daratumumab, bortezomib, or carfilzomib in RRMM patients ( Prof Sagar Lonial - Winship Cancer Institute of Emory University, Atlanta, USA )
14 Sep 2021
Should every transplant eligible NDMM patient receive a transplant?
Prof Morie Gertz - Mayo Clinic, Rochester, USA
Should every transplant eligible NDMM patient receive a transplant? ( Prof Morie Gertz - Mayo Clinic, Rochester, USA )
14 Sep 2021
Vaccinations in myeloma patients including for COVID-19
Prof Heinz Ludwig - Wilhelminen Cancer Research Institute, Vienna, Austria
Vaccinations in myeloma patients including for COVID-19 ( Prof Heinz Ludwig - Wilhelminen Cancer Research Institute, Vienna, Austria )
31 Aug 2021
CAPTIVATE: Fixed-duration first-line treatment with ibrutinib plus venetoclax fo...
Dr Rajat Bannerji - Rutgers Cancer Institute of New Jersey/RWJBarnabas Health, N...
CAPTIVATE: Fixed-duration first-line treatment with ibrutinib plus venetoclax for CLL/SLL ( Dr Rajat Bannerji - Rutgers Cancer Institute of New Jersey/RWJBarnabas Health, New Jersey, USA )
10 Jun 2021
Efficacy and safety of selpercatinib in RET fusion-positive cancers other than l...
Prof Vivek Subbiah - MD Anderson Cancer Center, Houston, USA
Efficacy and safety of selpercatinib in RET fusion-positive cancers other than lung or thyroid cancers ( Prof Vivek Subbiah - MD Anderson Cancer Center, Houston, USA )
13 Apr 2021
Real-world evidence of the use of carfilzomib among multiple myeloma patients ac...
Prof Evangelos Terpos - University of Athens, Athens, Greece
Real-world evidence of the use of carfilzomib among multiple myeloma patients across 10 European countries and Israel ( Prof Evangelos Terpos - University of Athens, Athens, Greece )
22 Dec 2020
Real-world evidence of the use of carfilzomib to refractory to lenalidomide pati...
Prof Evangelos Terpos - University of Athens, Athens, Greece
Real-world evidence of the use of carfilzomib to refractory to lenalidomide patients ( Prof Evangelos Terpos - University of Athens, Athens, Greece )
22 Dec 2020